GlassScriptPhysician profile
Gena D Nance
NPI 1992045363
$4,389.63
in general payments reported to CMS, 2019-2025
23 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $761 · 2022: $1,321 · 2023: $722 · 2024: $248 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,717.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.28 | 2021-2025 | Xifaxan, Plenvu |
| Madrigal Pharmaceuticals | $408.23 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $274.55 | 2021-2025 | Entyvio, Eohilia |
| Corcept Therapeutics | $227.92 | 2025 | Korlym |
| Novo Nordisk INC | $220.88 | 2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $139.61 | 2023-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $137.95 | 2025 | Axios |
| Genzyme Corporation | $125.00 | 2022 | |
| Sanofi Pasteur INC. | $115.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $107.10 | 2022 | |
| Braintree Laboratories, INC. | $83.52 | 2021-2023 | Sutab |
| Janssen Scientific Affairs, LLC | $67.03 | 2024 | Tremfya |
| Merck Sharp & Dohme LLC | $44.06 | 2022-2025 | Gardasil 9, Capvaxive |
| Gilead Sciences, INC. | $40.82 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $34.82 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $28.79 | 2025 | Voquezna |
| Qol Medical, LLC | $24.74 | 2025 | Sucraid |
| Ardelyx, INC. | $21.19 | 2023 | Ibsrela |
| Medtronic, INC. | $19.75 | 2023 | Interstim |
| Exact Sciences Corporation | $17.72 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $16.03 | 2025 | |
| Janssen Biotech, INC. | $14.59 | 2024 | Simponi Aria, Stelara, Simponi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gena Nance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.